A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

BACKGROUND: There is no consensus regarding optimal treatment for peripheral T-cell lymphomas (PTCL), especially in relapsed or refractory cases, which have very poor prognosis and a dismal outcome, with 5-year overall survival of 30 %. METHODS: A multicenter prospective phase II trial was conducted...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Hematol Oncol
Autors principals: Pellegrini, Cinzia, Dodero, Anna, Chiappella, Annalisa, Monaco, Federico, Degl’Innocenti, Debora, Salvi, Flavia, Vitolo, Umberto, Argnani, Lisa, Corradini, Paolo, Zinzani, Pier Luigi
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4830040/
https://ncbi.nlm.nih.gov/pubmed/27071522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0266-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars